deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 9-arm NCT02384954

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab

Sponsor: Altor BioScience

Conditions Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions N-803 Rituximab
Updated 14 times since 2017 Last updated: Jul 1, 2024 Started: Apr 17, 2015 Primary completion: Dec 13, 2020 Completion: Dec 13, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Change in drug product development strategy.

Other terminated trials from Altor BioScience

See all terminations from Altor BioScience

Listed as NCT02384954, this PHASE1/PHASE2 trial focuses on Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma and remains terminated or withdrawn. Sponsored by Altor BioScience, it has been updated 14 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Sep 2017 · 5 months · monthly snapshot~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Mar 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 9 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2017 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Apr 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Altor BioScience
Data source: Altor BioScience

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations